ASTRAZEN Stock Overview
A biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
AstraZeneca Pharma India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹6,895.75 |
| 52 Week High | ₹7,572.20 |
| 52 Week Low | ₹3,702.50 |
| Beta | 0.28 |
| 11 Month Change | 11.13% |
| 3 Month Change | 33.98% |
| 1 Year Change | 83.98% |
| 33 Year Change | 92.23% |
| 5 Year Change | 246.12% |
| Change since IPO | 1,030.45% |
Recent News & Updates
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03
Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22Recent updates
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Jul 12Shareholder Returns
| ASTRAZEN | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 10.3% | 3.9% | 2.4% |
| 1Y | 84.0% | 52.5% | 46.2% |
Return vs Industry: ASTRAZEN exceeded the Indian Pharmaceuticals industry which returned 52.5% over the past year.
Return vs Market: ASTRAZEN exceeded the Indian Market which returned 46.2% over the past year.
Price Volatility
| ASTRAZEN volatility | |
|---|---|
| ASTRAZEN Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: ASTRAZEN's share price has been volatile over the past 3 months.
Volatility Over Time: ASTRAZEN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 900 | Sanjeev Panchal | www.astrazeneca.in |
AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brand names; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brand names. The company also offers products in the areas of renal, metabolic, and immunology diseases.
AstraZeneca Pharma India Limited Fundamentals Summary
| ASTRAZEN fundamental statistics | |
|---|---|
| Market cap | ₹172.29b |
| Earnings (TTM) | ₹1.62b |
| Revenue (TTM) | ₹12.96b |
106.6x
P/E Ratio13.3x
P/S RatioIs ASTRAZEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASTRAZEN income statement (TTM) | |
|---|---|
| Revenue | ₹12.96b |
| Cost of Revenue | ₹5.95b |
| Gross Profit | ₹7.01b |
| Other Expenses | ₹5.39b |
| Earnings | ₹1.62b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 64.64 |
| Gross Margin | 54.11% |
| Net Profit Margin | 12.47% |
| Debt/Equity Ratio | 0% |
How did ASTRAZEN perform over the long term?
See historical performance and comparison